|
Palivizumab
resources
|
|
|
|
|
|
DRUG INFO
Palivizumab
Drug Name:
Palivizumab
Indication: For treatment of respiratory diseases casued by respiratory syncytial virus
Pharmacology: Synagis exhibits neutralizing and fusion-inhibitory activity against Respiratory syncytial virus (RSV). These activities inhibit RSV replication or spread. Synagis is given to prevent the development of lower respiratory tract disease in pediatric patients.
Mechanism Of Action: Binds to the outer coat or Fusion glycoprotein of RSV. This prevents its binding and uptake by host cellular receptors.
Drug Category: Antiviral Agents; monoclonal antibodies (08:18.24)
Brand Names/Synonyms: Synagis; anti-RSV; Synagis (MedImmune Inc)
Dosage Forms: POWDER FOR SOLUTION
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Humanized anti-RSV antibody
Chemical Formula: Not Available
Half Life: 18 days (in adults)
Drug Type: Approved Drug
# Accession No: BIOD00097
CAS Registry Number: 60574-4111-01
|
|
|
|
|
|
Palivizumab News
(When available)
Drug Executive With New Contract Leaves Jan 9, 2006
New York Times, ...and marketing, and was responsible for selling MedImmune products that included the nasal spray flu vaccine FluMist and the childhood respiratory drug Synagis. ...
RSV: It's common, contagious, disgusting Jan 8, 2006
Evansville Courier & Press (subscription), RSV. There is a special preventive injection called Synagis developed especially for high-risk infants. Ask your doctor about it. ...
Many Parents Unaware Of RSV: Tips On This Winter-Borne Virus Jan 9, 2006
Medical News Today (press release), ...who fall within the American Academy of Pediatrics' guidelines for RSV immunization are eligible for a prophylactic medication (brand name Synagis) that is ...
`Tis the season for high-risk baby virus Dec 23, 2005
Monsters and Critics.com, However, both doctors agreed that a monoclonal antibody, palivizumab (Synagis), appears to be the best treatment both to prevent the illness and, in some ...
PDL Grants Patent Licenses to Merck for Humanized Antibodies ... Jan 3, 2006
Yahoo! News (press release) ...(Synagis®); Roche (Zenapax®); and Wyeth (Mylotarg®). ... Xolair is a trademark of Novartis AG. Synagis is a registered US trademark of MedImmune, Inc. ...
Healthstar Public Relations Announces Staff Addition and ... Jan 10, 2006
PharmaLive.com (press release), ...worked on the pre- and post-launch activities for the Together Rx Access Card, a prescription savings card for uninsured Americans and Synagis, a monoclonal ...
PDL Grants Patent Licenses to Merck for Humanized Antibodies ... Jan 3, 2006
PR Newswire (press release), Inc. (Synagis(R)); Roche (Zenapax(R)); and Wyeth (Mylotarg(R)). Further information on PDL is available at http://www.pdl.com . ...
|
|
|
